1. Introduction {#sec1}
===============

Systemic lupus erythematosus (SLE) is one of the most complicated autoimmune diseases. It could involve almost all organs or systems and presents with protean clinical manifestations \[[@B1]\]. In general, SLE can be divided into several subgroups based on specific clinical features including age, gender, and autoantibodies pattern, and the prognosis of different subgroups varies \[[@B2]\]. Anti-Sm antibody is considered as the marker autoantibody for the diagnosis of SLE with reported positivity ranged from 15.4% to 21.8% \[[@B3], [@B4]\]. Anti-double stranded DNA (anti-dsDNA) antibody is another specific autoantibody for SLE and has been proven to be associated with disease activity of SLE \[[@B5]\]. In order to understand SLE better, the association between clinical features of SLE and other anti-extractable nuclear antigen (ENA) antibodies (e.g., anti-SSA, anti-SSB, anti-RNP, and anti-rRNP antibodies) had been investigated by many research groups \[[@B6], [@B7]\]. In our study, we analyzed the associations between clinical manifestations and autoantibody patterns in Chinese SLE patients based on the data from Chinese SLE Treatment and Research group (CSTAR) registry. CSTAR is the first online registry of Chinese SLE patients and is supported by the Chinese National Key Technology R&D Program. This registry has depicted major clinical characteristics of lupus in Chinese patients \[[@B8]\].

2. Methods and Patients {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

CSTAR launched the first registry project of Chinese SLE patients in 2009, which was approved by the Institute Review Board (IRB) of Peking Union Medical College Hospital (PUMCH). Other centers had received ethical approval by the local IRB. All investigators were trained for the diagnosis, history review, disease activity evaluation, laboratory examinations, data input, and sample collection by local or nationwide training programs. This ongoing registry had recruited 2170 Chinese SLE patients who fulfilled the SLE classification criteria revised by the American College of Rheumatology (ACR) in 1997 \[[@B9]\] during the period between April 2009 and February 2010. Patients were required to fulfill at least 4 of the following 11 criteria: (1) malar rash; (2) discoid rash; (3) photosensitivity; (4) oral or nasopharyngeal ulceration; (5) nonerosive arthritis involving 2 or more peripheral joints; (6) pleuritis or pericarditis; (7) nephropathy: persistent proteinuria \> 0.5 grams per day or cellular casts; (8) neurologic involvement: seizures or psychosis in the absence of offending drugs or known metabolic derangements; (9) hematologic involvement: hemolytic anemia with reticulocytosis or leukopenia (\<4,000/mm^3^ on ≥2 occasions) or lymphopenia (\<1,500/mm^3^ on ≥2 occasions) or thrombocytopenia (\<100,000/mm^3^) in the absence of offending drugs; (10) immunologic disorder: antibody to native double-stranded DNA in abnormal titer or presence of antibody to Sm nuclear antigen or positive finding of antiphospholipid antibodies; (11) positive antinuclear antibody. We confirmed positive finding of antiphospholipid antibodies by an abnormal serum level of IgG or IgM anticardiolipin antibodies, an abnormal serum level of anti-*β*2 glucoprotein I, or a positive test result for lupus anticoagulant. In this study, we analyzed baseline data of 2104 patients (including 190 male and 1914 female patients) ([Table 1](#tab1){ref-type="table"}).

2.2. Methods {#sec2.2}
------------

Each center of the CSTAR has provided uniform evaluations and recorded data following the same protocol and operational procedures. Clinical manifestations and systemic involvement of SLE patients were collected, evaluated, and the relevant data were entered into the online CSTAR registry database. Pulmonary arterial hypertension (PAH) was defined as a resting systolic PAP (PASP) ≥40 mmHg estimated by echocardiography \[[@B10]\] without chronic lung conditions, cardiac valvular, or cardiomyopathic complications. Interstitial lung disease (ILD) was detected by chest X-ray or computerized tomography without infective infiltrations. Patients who had ILD with known causes or PAH were excluded when the association between autoantibodies and ILD in this study was analyzed.

The autoantibodies were measured at the local labs of each center, including anti-nuclear antibody (ANA), anti-double stranded DNA (anti-dsDNA) antibody, anti-Sm antibody, anti-ribosomal RNA-protein (anti-rRNP) antibody, anti-SSA antibody, anti-SSB antibody, anti-u1 small-nuclear RNA-protein (anti-RNP) antibody, and anti-phospholipid (APL) antibody. Most centers detected ANA and anti-dsDNA antibody using immunofluorescence assay with Hep-2 cell line and anti-extractable nuclear antigen (ENA) antibody (including anti-Sm, anti-SSA, anti-SSB, anti-RNP, and anti-rRNP antibodies) was tested with immunoblotting assay. The APL antibody was tested using enzyme-linked immunosorbent assay (anticardiolipin and anti-*β*2 glucoprotein I antibody) or dilute Russell viper venom test (lupus anticoagulant) when anti-phospholipid syndrome was suspected but these tests were not mandatory.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Statistical analysis was performed by using SPSS 17.0 for WINDOWS. Positivity of autoantibodies in SLE patients with different clinical manifestations was expressed as patient number with percentage (%) in brackets ([Table 4](#tab4){ref-type="table"}). Chi-square tests were performed to detect the associations between clinical manifestations and autoantibody patterns. Since there was no expected frequency \<5, Fisher\'s exact test was not used. Cluster analysis with Ward\'s method was performed to investigate the relationship between autoantibodies. All tests of significance were two-sided and a *P* value of \< 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

The autoantibody profile of this study included the presence of ANA in 2063 (98.1%), anti-dsDNA antibody in 699 (33.2%), anti-Sm antibody in 350 (16.6%), anti-RNP antibody in 189 (8.9%), anti-SSA antibody in 497 (23.6%), anti-SSB antibody in 224 (10.7%), and anti-rRNP antibody in 255 (12.7%) cases. APL antibody was tested in 937 patients with a positivity of 44.1% (414/937). 199 patients (9.5%) were demonstrated to have both anti-SSA antibody and anti-SSB antibody and 142 patients (6.7%) have anti-Sm antibody and anti-RNP antibody, simultaneously ([Table 2](#tab2){ref-type="table"}).

Clinical manifestations found in our study included malar rash in 1009 (47.9%), discoid skin lesions in 118 (5.6%), photosensitivity in 526 (25.0%), oral ulcer in 466 (22.1%), arthritis in 1147 (54.5%), serositis in 345 (16.4%), nephropathy in 988 (47.4%), hematological involvement, including leukocytopenia, hemolytic anemia, and thrombocytopenia, in 1181 (56.1%), and neurological involvement (neuropsychological lupus) in 101 (4.8%) patients. The prevalence of ILD and PAH was 4.2% (86/2024) and 3.8% (74/1934), respectively in this registry database ([Table 3](#tab3){ref-type="table"}).

The association analysis between clinical manifestations and autoantibodies revealed that there were associations between anti-Sm antibody (*P* \< 0.001), anti-rRNP antibody (*P* \< 0.05), and malar rash; between anti-dsDNA antibody and nephropathy; between anti-RNP antibody, anti-SSA antibody and pulmonary arterial hypertension (PAH); and between anti-SSB antibody and hematological involvement (*P* \< 0.05). Significant associations were also found between anti-dsDNA antibody and a lower prevalence of photosensitivity and between anti-SSA antibody and a lower prevalence of nephropathy (*P* \< 0.05). APL antibody was associated with hematologic involvement, interstitial lung disease (ILD), and a lower prevalence of oral ulcerations (*P* \< 0.05) ([Table 4](#tab4){ref-type="table"}).

Using cluster analysis, we identified five clusters of antibodies. Cluster 1 consisted of antibodies to Sm and RNP and cluster 2 consisted of antibodies to SSA and SSB. Clusters 3, 4, and 5 consisted of antibodies to ribosomal P, dsDNA, and APL, respectively ([Figure 1](#fig1){ref-type="fig"}).

4. Discussion {#sec4}
=============

Diffuse connective tissue diseases (CTDs) are characterized by the presentation of specific profiles of autoantibodies, and SLE is the prototype of diffuse CTDs, which could involve almost all systems \[[@B1]\]. The typical pathological feature of SLE is systemic vasculitis with immune complex deposition \[[@B11]\]. It is rational to propose that some autoantibodies may be associated with specific clinical features of SLE.

Anti-dsDNA has been proven to be a pathogenic autoantibody in SLE and has been reported to be associated with renal damage, leukopenia, anemia, and urine cellular casts in SLE patients \[[@B6], [@B7], [@B12]\]. Chien et al. discovered that there were associations between anti-dsDNA antibodies and multiple clinical manifestations of SLE patients, such as Raynaud\'s phenomenon, photosensitivity, arthritis, hypocomplementemia, thrombocytopenia, proteinuria, and serositis, but with a small number of patients (80 patients) \[[@B13]\]. Our study confirmed that anti-dsDNA was associated with nephropathy ([Table 4](#tab4){ref-type="table"}) which was also reported by Lu et al. and Alba et al. \[[@B12], [@B14]\]. The association between anti-dsDNA antibody and a lower prevalence of photosensitivity observed in our study was contradictory to Smikle et al. \[[@B4]\]. The difference may be due to different ethnical background and sample size.

As a marker autoantibody of SLE, anti-Sm antibody was found to be associated with malar rash, discoid rash, pericarditis, and leukopenia in studies by Tang et al. and Lu et al. \[[@B7], [@B12]\] However, the pathogenic characteristics of anti-Sm antibody were controversial \[[@B6], [@B12], [@B14], [@B15]\]. Our study also revealed the association of anti-Sm antibody with malar rash, and malar rash is a characteristic skin lesion of SLE patients. But the association between anti-Sm antibody and other organ damage could not be detected in our study ([Table 4](#tab4){ref-type="table"}).

Anti-RNP antibody was thought to be related to Raynaud\'s phenomenon and PAH by many physicians. The association between anti-RNP and Raynaud\'s phenomenon was confirmed by Hoffman et al. and Tang et al. \[[@B6], [@B7]\]. Both Raynaud\'s phenomenon and anti-RNP antibody are considered as risk factors for PAH associated with CTDs and represent the presence of vasculopathy \[[@B16]\]. Anti-RNP antibody was also found to be associated with photosensitivity \[[@B7]\], lymphopenia \[[@B12]\], and leukopenia \[[@B6]\]. In our study, the Raynaud\'s phenomenon was not included in the clinical manifestations analysis, but the association between anti-RNP antibody and PAH in patients with SLE was discovered ([Table 4](#tab4){ref-type="table"}).

Anti-SSA and anti-SSB antibody are frequently found in SLE patients with the positivity ranged from 34% to 83% in different reports \[[@B8], [@B17]\] and higher prevalence of anti-SSA/SSB antibody could be observed in SLE patients associated with secondary Sjogren\'s syndrome \[[@B18]\]. Anti-SSA antibody was found to be associated with neonatal heart block \[[@B19]\], xerophthalmia/xerostomia, and photosensitivity \[[@B20]\]. Anti-SSB body was found to be associated with hematological disorder, proteinuria, malar rash \[[@B12]\], and pericarditis \[[@B6]\]. In this study, we found the associations between anti-SSA antibody and PAH, between anti-SSB antibody and hematological involvement, and between anti-SSA antibody and a lower prevalence of nephropathy ([Table 4](#tab4){ref-type="table"}). This study is the first report that anti-SSA antibody might be a predictor of PAH in SLE patients according to our knowledge. Since we have known that anti-SSA antibody is one of the diagnostic criteria for Sjogren\'s syndrome \[[@B21]\] and PAH is also a rare manifestation of patients with primary Sjogren\'s syndrome \[[@B22]\], we propose that more attention should be paid to screen for PAH in SLE patients with anti-SSA antibody. But further studies are needed to clarify this association in the future. The association between anti-SSA antibody and a lower prevalence of lupus nephritis was reported by Chien and coresearchers in a small sample size study \[[@B13]\] and Tapanes et al. found that anti-SSA antibody may correlate with favorable prognosis of lupus nephritis \[[@B23]\]. But Vila et al. found the opposite results in 201 Puerto Ricans patients with SLE \[[@B24]\]. We confirmed the association between anti-SSA antibody and a lower prevalence of nephropathy in Chinese SLE patients and this association may suggest a protective role of anti-SSA antibody in lupus nephritis. The hematological disorder in SLE patients with positive anti-SSB antibody was primarily thrombocytopenia in our study and the association between anti-SSB antibody and thrombocytopenia was reported by Unal et al. in a case report \[[@B25]\]. Large sample studies are needed to clarify the real association between the hematological disorders and anti-SSB antibody.

Anti-rRNP antibody is regarded as a specific autoantibody of SLE \[[@B26]\] and it is thought to be associated with neuropsychological manifestations of SLE patients \[[@B27]\]. This relationship was not proven in our study, what may be due to the small amount of patients with neuropsychological manifestations in our registry. The association of anti-rRNP antibody and malar rash was found in our study ([Table 4](#tab4){ref-type="table"}), which was consistent with anti-Sm antibody.

The APL antibody was tested in 937 patients when antiphospholipid syndrome was suspected in our cohort study. The association between APL antibody and hematological involvement (mainly thrombocytopenia) was deductible since phospholipid is an innate component of blood cells. McClain and coresearchers have found that APL antibody appeared prior to diagnosis of SLE and this group of autoantibodies are associated with many SLE features, including malar rash, discoid lesions, photosensitivity, renal disorder, neurological disorder, hemolytic anemia, and thrombocytopenia \[[@B28]\]. Saches and coresearchers have demonstrated that APL antibody is associated with spontaneous abortion, thrombocytopenia, livedo reticularis, and a positive direct Coombs\' test in SLE patients \[[@B29]\]. The association between APL antibody and ILD found in our study may be related to the microvessel injuries resulted from microemboli or immune-complex deposition ([Table 4](#tab4){ref-type="table"}). Kanakis et al. have reviewed the pulmonary manifestations in patients with antiphospholipid syndrome including fibrosing alveolitis \[[@B30]\]. We confirmed the association between antiphospholipid antibody and ILD, which is a rare feature of SLE. Neurological involvement in SLE patients is thought to be correlated with APL antibody \[[@B31], [@B32]\], but previous studies have not shown this association \[[@B28], [@B29]\], perhaps due to the low incidence of neuropsychological lupus in SLE patients. We demonstrated a tendency (*P* = 0.061) of association between APL antibody and neurological involvement in our study ([Table 4](#tab4){ref-type="table"}). Further studies with more patients are needed.

Using cluster analysis, we identified five clusters of autoantibodies. Antibodies to Sm and RNP clustered together early. Cluster 2 consisted of antibodies to SSA and SSB. The other clusters consisted of individual antibodies to ribosomal P (rRNP), dsDNA, and APL, respectively ([Figure 1](#fig1){ref-type="fig"}). Our result is in accordance with previous studies \[[@B6], [@B33]\].

We summarize the associations with statistical significance between specific autoantibodies and clinical manifestations revealed by different study groups in [Table 5](#tab5){ref-type="table"}. Most of our findings are consistent with studies in the literature, but the associations between anti-RNP antibody and PAH; between anti-SSA and PAH; and between APL antibody and ILD were first discovered by our study. We always repeated echocardiography if PAH was suspected in the first echocardiogram examination. Right heart catheter (RHC) is not feasible for general screening and repeated measurements due to its invasive characteristic but RHC is used for confirming the diagnosis of PAH according to the guideline. As far as we know, most of the 74 patients with a preliminary diagnosis of PAH identified in our study have been referred for confirmatory RHC, but these results were not recorded in the registry. This is a limitation of our study \[[@B34]\].

5. Conclusion {#sec5}
=============

As the largest registry cohort study in China, CSTAR has already disclosed some clinical profiles of Chinese SLE patient \[[@B8], [@B34]\]. Confirmation of the associations between clinical manifestations and specific autoantibodies found in our study can help physicians to understand the features of SLE patients better, especially in China. A thorough screening of ANA and anti-ENA antibodies when the diagnosis of SLE is established can help us to predict organ damage. We could focus on the specific autoantibody-related vital organ complications (e.g., PAH) in the follow-up of SLE patients. We suggest that repeating echocardiography annually may help to discover PAH at the early stage in SLE patients with anti-RNP and/or anti-SSA antibody. Early diagnosis of PAH in patients with SLE is important for initiating effective interventions to prevent malignant outcomes (e.g., heart failure).
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###### 

The baseline characteristics of 2104 SLE patients from CSTAR cohort study.

                                                                        \%
  ------------------------------------- ------------------------------- ------
  Female                                1914                            91.0
  Male                                  190                             9.0
  Age at onset (years)                  29.2 ± 12.1 (range 1.4\~68.9)    
  Age at diagnosis (years)              30.3 ± 12.3 (range 4\~77)        
  Age at entry (years)                  32.7 ± 12.7 (range 5\~78)        
  Disease duration (months)             41.9 ± 58.8 (range 1\~468)       
  SLE disease activity index at entry                                    
   0\~4                                 532                             25.3
   5\~9                                 587                             27.9
   10\~14                               591                             28.1
   \>14                                 394                             18.7

###### 

The profile of autoantibodies in 2104 SLE patients from CSTAR cohort study.

                                                           Patients number   Positivity (%)
  -------------------------------------------------------- ----------------- ----------------
  Anti-nuclear antibody (ANA)                              2063              98.1
  Anti-double stranded DNA (anti-dsDNA) antibody           699               33.2
  Anti-Sm antibody                                         350               16.6
  Anti-SSA antibody                                        497               23.6
  Anti-SSB antibody                                        224               10.7
  Anti-u1 small-nuclear RNA-protein (anti-RNP) antibody    189               8.9
  Anti-ribosomal RNA-protein (anti-rRNP) antibody          255               12.7
  Anti-phospholipid (APL) antibody                         414/937^\$^       44.1
  Anti-SSA and anti-SSB antibody positive simultaneously   199               9.5
  Anti-Sm and anti-RNP antibody positive simultaneously    142               6.7

^\$^Actually detected number of patients.

###### 

The profile of clinical manifestations in 2104 SLE patients from CSTAR cohort study.

                                                Patients number   Positivity (%)
  --------------------------------------------- ----------------- ----------------
  Malar rash                                    1009              47.9
  Discoid lesions                               118               5.6
  Photosensitivity                              526               25.0
  Oral ulcerations                              466               22.1
  Arthritis                                     1147              54.5
  Serositis                                     345               16.4
  Nephropathy                                   998               47.4
  Hematological involvement (hematocytopenia)   1181              56.1
  Neurological involvement                      101               4.8
  Interstitial lung disease                     86/2024^\$^       4.2
  Pulmonary arterial hypertension               74/1934^\$^       3.8

^\$^Actually detected number of patients.

###### 

Associations between specific autoantibodies and clinical manifestations of SLE \[patient number (%)\].

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                              Anti-dsDNA      Anti-Sm   Anti-RNP       Anti-SSA    Anti-SSB       Anti-rRNP   APL                                                                                             
  --------------------------- --------------- --------- -------------- ----------- -------------- ----------- ------------------- --------- -------------- --------- -------------- --------- --------------- -----------
  Patients number             699\                      350\                       189\                       497\                          224\                     255\                     414\             
                              (100)                     (100)                      (100)                      (100)                         (100)                    (100)                    (100)           

  Malar rash                  315\            0.061     201\           \<0.001\*   91\            0.956       241\                0.785     105\           0.732     151\           0.004\*   187\            0.275
                              (45.06)                   (57.43)                    (48.15)                    (48.49)                       (46.88)                  (59.22)                  (45.17)         

  Discoid lesions             31\             0.099     22\            0.546       13\            0.426       25\                 0.522     11\            0.631     13\            0.855     20\             0.540
                              (4.43)                    (6.29)                     (6.88)                     (5.03)                        (4.91)                   (5.10)                   (4.83)          

  Photosensitivity            150\            0.008\*   95\            0.311       47\            0.965       132\                0.358     67\            0.073     69\            0.752     96\             0.509
                              (21.46)                   (27.14)                    (24.87)                    (26.56)                       (29.91)                  (27.06)                  (23.19)         

  Oral ulcerations            151\            0.671     87\            0.181       42\            0.980       108\                0.797     48\            0.784     48\            0.395     74\             0.035\*
                              (21.6)                    (24.86)                    (22.22)                    (21.73)                       (21.43)                  (18.82)                  (17.87)         

  Arthritis                   399\            0.095     193\           0.796       106\           0.650       268\                0.762     119\           0.658     146\           0.765     236\            0.289
                              (57.08)                   (55.14)                    (56.08)                    (53.92)                       (53.13)                  (57.25)                  (57.00)         

  Serositis                   119\            0.584     55\            0.705       31\            0.999       89\                 0.298     46\            0.077     35\            0.428     61\             0.996
                              (17.02)                   (15.71)                    (16.40)                    (17.91)                       (20.54)                  (13.73)                  (14.73)         

  Nephropathy                 355\            0.030\*   155\           0.196       91\            0.837       216\                0.042\*   102\           0.547     120\           0.817     191\            0.848
                              (50.79)                   (44.29)                    (48.15)                    (43.46)                       (45.54)                  (47.06)                  (46.14)         

  Hematological involvement   403\            0.321     196\           0.957       108\           0.769       278\                0.920     141\           0.030\*   137\           0.542     273\            \<0.001\*
                              (57.65)                   (56.00)                    (57.14)                    (55.94)                       (62.95)                  (53.73)                  (65.94)         

  Neurological involvement    26\             0.102     18\            0.743       12\            0.296       21\                 0.493     13\            0.457     16\            0.335     32\             0.061
                              (3.72)                    (5.14)                     (6.35)                     (4.23)                        (5.80)                   (6.27)                   (7.73)          

  ILD                         29/675^\$^ \    0.941     18/326^\$^ \   0.214       11/181^\$^ \   0.201       21/481^\$^ \        0.884     12/209^\$^ \   0.259     12/250^\$^ \   0.940     29/398^\$^  \   \<0.001\*
                               (4.30)                    (5.52)                     (6.08)                     (4.37)                        (5.74)                   (4.80)                  (7.29)          

  PAH                         24/661^\$^  \   0.747     16/322^\$^ \   0.242       12/180^\$^ \   0.037\*     28/469^\$^ (5.97)   0.005\*   11/205^\$^ \   0.224     5/237^\$^ \    0.151     15/387^\$^ \    0.714
                              (3.63)                     (4.97)                     (6.67)                                                   (5.37)                   (2.11)                   (3.88)         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*P*: *P* value; Anti-dsDNA: Anti-double stranded DNA antibody; Anti-Sm: Anti-Sm antibody; Anti-SSA: Anti-SSA antibody; Anti-SSB: Anti-SSB antibody; Anti-RNP: Anti-u1 small-nuclear RNA-protein antibody; Anti-rRNP: Anti-ribosomal RNA-protein antibody; APL: Anti-phospholipid antibody; PAH: pulmonary arterial hypertension; ILD: interstitial lung disease.

^\$^Actually detected number of patients.

\**P* \< 0.05.

###### 

Associations with statistical significance between specific autoantibodies and clinical manifestations in SLE patients.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author            Number of patients   Geographical area   Anti-dsDNA              Anti-Sm              Anti-RNP           Anti-SSA            Anti-SSB         Anti-rRNP    APL
  ----------------- -------------------- ------------------- ----------------------- -------------------- ------------------ ------------------- ---------------- ------------ -------------------
  Chien et al.\     80                   Asia, China         Raynaud\'s\                                                     Photosensitivity\                                  
  \[[@B13]\]                                                 phenomenon\                                                     Anemia                                            
                                                             Photosensitivity\                                                                                                 
                                                             Arthritis\                                                                                                        
                                                             Thrombocytopenia\                                                                                                 
                                                             Hypocomplementemia\                                                                                               
                                                             Proteinuria\                                                                                                      
                                                             Serositis                                                                                                         

                                                                                                                                                                               

  McClain et al.\   130                  United states                                                                                                                         Malar rash\
  \[[@B28]\]                                                                                                                                                                   discoid lesions\
                                                                                                                                                                               photosensitivity\
                                                                                                                                                                               renal disorder\
                                                                                                                                                                               neurological\
                                                                                                                                                                               disorder\
                                                                                                                                                                               hemolytic anemia\
                                                                                                                                                                               thrombocytopenia

                                                                                                                                                                               

  Vila et al.\      201                  Puerto Ricans       Vasculitis\             Skin ulcerations\                       Discoid rash\                                      
  \[[@B24]\]                                                 Pericardial effusion\   Elevated liver\                         Serositis\                                        
                                                             Renal involvement\      enzymes\                                Pneumonitis\                                      
                                                             Anaemia\                Renal involvement\                      Elevated liver\                                   
                                                             Leukocytopenia\         Thrombocytopenia                        enzymes\                                          
                                                             Lymphocytopenia\                                                Hemolytic\                                        
                                                             Thrombocytopenia                                                anaemia\                                          
                                                                                                                             Leukocytopenia\                                   
                                                                                                                             Lymphocytopenia                                   

                                                                                                                                                                               

  Hoffman et al.\   289                  Europe, Belgium     Urine cellular casts                         Raynaud\'s\        Xerostomia          Xerostomia\                    
  \[[@B6]\]                                                                                               phenomenon\                            Pericarditis                  
                                                                                                          Leukocytopenia                                                       

                                                                                                                                                                               

  Tang et al.\      917                  Asia, China         Renal disorder\         Malar rash\          Raynaud\'s\                                                           
  \[[@B7]\]                                                  Leukocytopenia\         Discoid rash\        phenomenon\                                                          
                                                             Anemia                  Pericarditis\        Photosensitivity                                                     
                                                                                     Leukocytopenia                                                                            

                                                                                                                                                                               

  Lu et al.\        1803                 United states       Renal disease\          Leukocytopenia\                         Hematological\      Hematological\                 
  \[[@B12]\]                                                 Urine cellular casts                                            disorder\           disorder\                     
                                                                                                                             Lymphocytopenia\    Proteinuria\                  
                                                                                                                                                 Malar rash                    

                                                                                                                                                                               

  CSTAR             2104                 Asia, China         Photosensitivity\       Malar rash           PAH\               Nephropathy\        Hematological\   Malar rash   Oral ulceration\
                                                             Nephropathy                                                     PAH                 disorder                      hematological\
                                                                                                                                                                               disorder\
                                                                                                                                                                               ILD
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ANA: Anti-nuclear antibody; Anti-dsDNA: Anti-double stranded DNA antibody; Anti-Sm: Anti-Sm antibody; Anti-SSA: Anti-SSA antibody; Anti-SSB: Anti-SSB antibody; Anti-RNP: Anti-u1 small-nuclear RNA-protein antibody; Anti-Rrnp: Anti-ribosomal RNA-protein antibody; APL: Anti-phospholipid antibody; PAH: pulmonary arterial hypertension; ILD: interstitial lung disease.
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